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SUMMARY
CD4+ T helper (Th) cell activation is essential for inducing cytotoxic T lymphocyte (CTL) responses against malignancy. We reprog-
rammed a Th clone specific for chronicmyelogenous leukemia (CML)-derived b3a2 peptide to pluripotency and re-differentiated the cells
into original TCR-expressing T-lineage cells (iPS-Tcells) with gene expression patterns resembling those of group 1 innate lymphoid cells.
CD4 gene transduction into iPS-T cells enhanced b3a2 peptide-specific responses via b3a2 peptide-specific TCR. iPS-T cells upregulated
CD40 ligand (CD40L) expression in response to interleukin-2 and interleukin-15. In the presence of Wilms tumor 1 (WT1) peptide, an-
tigen-specific dendritic cells (DCs) conditioned by CD4-modified CD40Lhigh iPS-T cells stimulated WT1-specific CTL priming, which
eliminated WT1 peptide-expressing CML cells in vitro and in vivo. Thus, CD4 modification of CD40Lhigh iPS-T cells generates innate
lymphoid helper-like cells inducing bcr-abl-specific TCR signaling that mediates effectiveanti-leukemic CTL responses via DC matura-
tion, showing potential for adjuvant immunotherapy against leukemia.
INTRODUCTION
Tumor antigen-specific CD4+ T helper (Th) cells can induce
a wide range of tumor antigen-specific cytotoxic T lympho-
cyte (CTL) responses via the maturation of dendritic cells
(DCs), which avoid tumor evasion because of a mutation
in a single target epitope (Kreiter et al., 2015). In addition,
Th cells can attenuate the immunosuppressive properties
of the tumor microenvironment by altering the cytokine
milieu (Kim and Cantor, 2014). Therefore, adoptive T cell
therapy using ex vivo expanded antigen-specific CD4+ Th
cells may be a promising therapeutic strategy for refractory
malignant tumors including hematological malignancies.
However, clinical application is limited by the difficult
isolation of CD4+ Th cells specific for relevant antigens
and limited proliferative potential of these cells.
This problem may be solved by using induced pluripo-
tent stem cell (iPSC) technology. We and others have re-
ported methods for establishing iPSCs from mature anti-
gen-specific T cells and re-differentiating the iPSCs into
CD8+ Tcells or invariant Tcells with the same Tcell antigen
receptor (TCR) as the original T cells (Kitayama et al., 2016;
Nishimura et al., 2013; Vizcardo et al., 2013; Wakao et al.,
2013). The proliferative potential of iPSCs may provide a
sufficient number of CD4+ Th cells for cancer treatment.
CD40 ligand (CD40L), which is expressed on activated
CD4+ Th cells, is critical for inducing DC maturation via
the CD40-CD40L interaction (Bennett et al., 1997, 1998;
Boise et al., 1995; Ridge et al., 1998; Schoenberger et al.,
1998; Summers deLuca and Gommerman, 2012; Wiesel
and Oxenius, 2012). Recently, the expression of CD40L
on other types of immune cells known as innate lymphoid
cells (ILCs) was reported (Magri et al., 2014;McKenzie et al.,
2014; Summers deLuca andGommerman, 2012). ILCs play
a fundamental role in the immune systemnot only by initi-
ating, regulating, and resolving inflammation, but also by
modulating adaptive immunity (Sonnenberg and Artis,
2015). Although they lack TCRs, ILCs show T helper prop-
erties similar to Th1, Th2, Th17, and Th22 cells in terms
of their cytokine profiles and transcription factors, which
determine their development (McKenzie et al., 2014). The
contributionof ILCs topathogen control andpathogenesis,
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along with their similarity and redundancy to acquired im-
mune cells, are current of interest in immunology research
(Cording et al., 2016).
In the present study, we established iPSCs from a CD4+
Th1 clone specific for the junction region of BCR-ABL
p210 (b3a2), a leukemia antigen, which is restricted by
HLA class II (HLA-DR9) (Ueda et al., 2016). We induced
re-differentiation of iPSCs to T-lineage cells expressing
HLA class II-restricted TCR (iPS-T cells). The gene expres-
sion profile of iPS-T cells differed from that of abTCR+
T cells and resembled a subset of ILCs. By transferring
CD4 molecule to iPS-T cells and optimizing the ex vivo
culture conditions to induce iPS-T cells with high CD40L
expression, we successfully generated innate lymphoid
helper-like cells that activated leukemic antigen-specific
CTLs via DC maturation in a TCR-dependent antigen-spe-
cific manner. The activated CTLs showed effective anti-
leukemic activity.
Our findings indicate that functional helper-like cells can
be acquired from iPS-T cells through genetic modification
and purification of the population. Therefore, CD40Lhigh
CD4+ iPS-Tcells are a potential platform for novel adjuvant
cell therapy against malignant tumors.
RESULTS
ILC-like Properties of T-Lineage Cells Differentiated
from CD4+ Th1 Clone-Derived iPSCs
We previously established an HLA-DR9-restricted leukemia
antigen (b3a2)-specific CD4+ Th1 clone (SK). Using our
T cell regeneration protocol with slight modifications
(Figure S2A), we obtained CD3+ CD45+ CD5dim+ CD7+
CD8adim+ CD8b cells from CD4+ Th1 clone (SK)-derived
iPSCs (Figure 1A, left panel). The cells did not express
CD4 throughout cell processing and heterogeneously
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Figure 1. Re-differentiation and CD4 Modification of
T-Lineage Cells from CD4+ Th1 Clone-Derived iPSCs
Exert HLA Class II-Restricted Responses
(A) Representative flow cytometry profiles of the indicated
molecules on the original CD4+ Th clone (SK) and regen-
erated T cells (iPS-T cells) after 14 days of phytohemag-
glutinin (PHA)-P stimulation.
(B) Principal component analysis of expression profiles of
146 selected T cell/ILC-related genes (Table S3).
(C) GATA3, RORC, and TBX21 expression in the indicated
population. mRNA expression levels were determined by
RNA sequencing.
(D) Hierarchical clustering of expressions of 22 selected
genes related to ILC subsets.
(E) Cytokine production of the original CD4+ Th1 clone (SK)
and iPS-T cells. T cells were stimulated with plate-bound
control immunoglobulin (immunoglobulin G [IgG]) or
anti-CD3 mAb (10 mg/mL) for 24 hr. The indicated cyto-
kines in the culture supernatant were measured by ELISA.
Data shown are the means ± SD of triplicate cultures and
are representative of two independent experiments.
(F) Representative flow cytometry profiles of CD4 and TCR-
Vb22 expression on the original CD4+ Th1 clone (SK), Mock
transduced iPS-T cells (Mock iPS-T cells), and CD4-trans-
duced iPS-T cells (CD4+ iPS-T cells).
(G) Proliferative responses of Mock iPS-T cells and CD4+
iPS-T cells to antigenic peptide. T cells were co-cultured
with autologous PBMCs in the presence of b3a2 peptide
(10 mM) and measured by the [3H]thymidine incorporation
assay. Data shown are the means and are representative of
two independent triplicate experiments.
(H) b3a2 peptide-specific IFN-g production by Mock iPS-T
cells and CD4+ iPS-T cells. Mock iPS-T cells and CD4+ iPS-T
cells (13 105) were co-cultured for 24 hr with autologous DCs (53 104) that had been prepulsed with b3a2 peptide (10 mM). IFN-g in the
culture supernatant (24 hr) was measured by ELISA. Data shown are the means ± SD of triplicate cultures and are representative of two
independent experiments.
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expressed several ILC markers including CD56, CD161,
NKG2D, c-Kit, NKp30, NKp44, NKp46, and DNAM-1 (Fig-
ure 1A, right panel). Despite their heterogeneity, the cells
consistently expressed the same TCR as the original CD4+
Th1 clone (SK) (Figure S2B). Based on the expression of
CD161 and c-Kit, iPS-T cells were divided into four subpop-
ulations (Figure S2C), and their global RNA expression pat-
terns were compared with those of natural killer (NK) cells,
type 1 ILCs (ILC1s), type 2 ILCs (ILC2s), type 3 ILCs
(ILC3s), abT cells, and gdT cells isolated from peripheral
blood (Figure S2D). iPS-T cells had genetic properties
more consistent with those of ILC1s, NK cells, and gdTcells
than those of peripheral abT cells (Figure S2E; Table S2).
The expression of genes related to T cell and ILC functions
in iPS-T cells were similar to those in NK cells or ILC1s (Fig-
ures 1B and S2F; Table S3). Gene ontology and Kyoto Ency-
clopedia of Genes and Genomes pathway analysis revealed
enrichment of genes related to ‘‘NK cell-related cytotox-
icity’’ in iPS-T cells, NK cells, and ILC1s (Table S4). All sub-
populations of iPS-T cells expressed relatively low levels of
BCL11B, an essential transcription factor for T cell differen-
tiation, compared with abT cells, but relatively high levels
of ID2 and ZBTB16, which are transcription factors for
ILCs (Figures S2G and S4F) (Naito et al., 2011; Spits et al.,
2013). All subpopulations commonly expressed ILC1-
related genes, such as NCAM1, NCR1, NCR2, ICOS, and
IL12RB2, but low levels of IL7R and IL1R, which are ex-
pressed on all ILCs except NK cells (Figure 1D) (Spits
et al., 2013). The ILC1/NK-like genetic properties of iPS-T
cells, indicated by the relatively high expression of
TBX21 and relatively low expression of GATA3 and
RORC, were confirmed by the reads per kilobase million
value and qRT-PCR analysis (Figure 1C, and data not
shown). As reported previously, our iPS-T cells exhibited
TCR-independent NK cell-like cytotoxicity (Figure S2H)
(Kitayama et al., 2016; Yamada et al., 2016). The iPS-T cells
produced high levels of interferon-g (IFN-g), comparatively
low levels of interleukin-4 (IL-4), and no IL-17, which are
similar to the original CD4+ Th1 clone (SK) (Figure 1E). In
addition, iPS-T cells were expanded by up to several thou-
sand-fold by two rounds of phytohemagglutinin (PHA)-P
stimulation (Figure S2I). These data suggest that iPS-T cells
generated from the CD4+ Th1 clone have group 1 ILC-like
properties despite their expression of TCR.
CD4 Modification Augments b3a2-Specific Responses
in iPSC-Derived T Cells
During T cell activation, the binding of CD4 to HLA class
II increases TCR signaling 30- to 300-fold (Janeway, 1992),
suggesting that CD4 is essential for the complete activa-
tion of Th cells. Because our iPS-T cells expressed HLA
class II-restricted TCR from the original CD4+ Th1 clone
(SK), we hypothesized that transduction of the CD4
gene in iPS-T cells results in enhanced TCR-dependent re-
sponses by peptide stimulation. We transduced the CD4
gene using a retroviral vector (Figure 1F). CD4-transduced
iPS-T cells (CD4+ iPS-T cells) showed an antigen-depen-
dent proliferative response and cytokine production
restricted by HLA-DR9 (Figures 1G, 1H, and S3A), which
was consistent with the response of the original CD4+
Th1 clone (SK) (Figures S3B–S3D). In contrast, iPS-T cells
without CD4 transduction (Mock iPS-T cells) showed
impaired proliferation and IFN-g production (Figures 1G
and 1H). Moreover, we confirmed that the acquired func-
tions of CD4+ iPS-T cells did not depend on the specific
positional effect of integrated retroviral vectors (Fig-
ure S3E). The effect of CD4 modification was also vali-
dated in iPS-T cells derived from an HLA-DR53-restricted
GAD65113-131 peptide-specific CD4
+ Th clone (SA32.5)
(Figures S4A–S4E) (Tabata et al., 1998). Next, we analyzed
the global gene expression profiles of Mock iPS-T cells and
CD4+ iPS-T cells stimulated with b3a2 peptide- or vehicle-
loaded THP-1-expressing HLA-DR9 (THP-1-DR9) cells. The
gene expression profile of CD4+ iPS-T cells stimulated
by b3a2 peptide differed from that of cells without b3a2
peptide and/or CD4 transduction (Figures S5A and S5B,
Table S5). Gene ontology analysis revealed that categories
related to cell proliferation were significantly upregulated
in b3a2-stimulated CD4+ iPS-T cells compared with b3a2-
stimulated Mock iPS-T cells (Figure S5C). These data
collectively indicate that CD4 gene modification gives
iPS-T cells an enhanced ability to exert b3a2 peptide-spe-
cific and HLA class II-restricted responses.
Identification of a CD40Lhigh Population that
Efficiently Exerts Adjuvant Function
CD40L expression on activated CD4+ Th cells is critical for
the maturation of DCs, which provide costimulatory sig-
nals for effective activation and enhanced survival of anti-
gen-specific CD8+ T cells (Bennett et al., 1997, 1998; Boise
et al., 1995; Ridge et al., 1998; Schoenberger et al., 1998;
Wiesel and Oxenius, 2012). In addition to CD4+ Th cells,
IL-7 plus IL-1b primed murine ILC3 cells (Magri et al.,
2014) and IL-2-activated human NK cells (Carbone et al.,
1997) were reported to express functional levels of
CD40L. We hypothesized that iPS-T cells express CD40L
under stimulation by IL-2 receptor subunit g (common g
chain), which binds to other ligand (IL-2, 4, 7, 9, 15, 21)-
specific receptors. We detected preferential expression of
CD40LG and simultaneous expression of partner cytokine
receptors for common g chain including IL2RA, IL2RB,
IL2RG, and IL15RA in the c-Kit+ CD161+ subpopulation
(Figure S5D and data not shown). We cultured iPS-T cells
in several combinations of common g chain cytokines
and found that IL-2 in combinationwith IL-15 upregulated
CD40L expression (Figures 2A and 2B).
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The IL-2/IL-15-induced CD40Lhigh and CD40Llow popu-
lations were separated and expanded by PHA-P stimula-
tion. Each CD40Lhigh and CD40Llow population from
Mock iPS-T cells and CD4+ iPS-T cells expressed TCR-Vb22
and retained their CD40L expression levels in the presence
of IL-2 and IL-15 (Figures 2C and 2D). Upon stimulation
with an anti-CD3 antibody, only CD40Lhigh iPS-T cells
showed upregulated CD40L expression (Figures 2E and
2F). CD40Lhigh CD4+ iPS-T cells produced higher levels of
IFN-g and tumor necrosis factor alpha (TNF-a) than did
CD40Llow CD4+ iPS-Tcells, but the two populations consis-
tently produced low levels of IL-2, IL-4, IL-6, IL-10, and
IL-17 (Figures 2G and S6A). When stimulated with b3a2-
peptide-loaded DCs, co-expression of CD4 and CD40L syn-
ergistically enhanced the production of IFN-g and TNF-a,
indicating a Th1-biased cytokine profile (Figure S6B). In
addition, when CD40Lhigh CD4+ iPS-T cells were co-
cultured with THP-1-DR9 cells expressing BCR-ABL p210
protein, they produced IFN-g and TNF-a, indicating their
ability to respond to the naturally processed BCR-ABL
p210 epitope (Figures 2H and 2I). CD40Lhigh CD4+ iPS-T
cells can expand against repeated stimulation without
affectingCD3, CD5dim, CD7, andCD8a expression (Figures
S6C and S6D). Similar findings associated with CD40L
expression were obtained in iPS-T cells from an HLA-
DR53-restricted GAD65113-131 peptide-specific CD4
+ Th
clone (SA32.5) (Figures S7A–S7E). Collectively, we identi-
fied a population of CD4+ iPS-T cells with upregulated
CD40L expression in response to TCR stimulation and
possessed a superior ability to respond to antigenic peptide
stimulation.
Next, we analyzed the cellular adjuvant function of CD4+
iPS-T cells to induce DC maturation. When CD40Lhigh
CD4+ iPS-T cells were co-cultured with immature DCs pre-
pulsed with b3a2 peptide, they induced maturation of
DCs (Figures 3A and S7F). In contrast, DC maturation by
CD40Llow CD4+ iPS-T cells was impaired (Figures 3A and
S7F). Furthermore, CD40Llow Mock iPS-T cells failed to
induce DC maturation, possibly via impaired recognition
of the HLA class II/peptide complex because of the absence
of CD4 (Figures 3A and S7F). CD40Lhigh CD4+ iPS-T cells
also enhanced the production of IL-12p70, CXCL9, and
CXCL11, which are important soluble factors in the activa-
tion and migration of NK cells, Th1 cells, and CTLs (Fig-
ure 3B). These data indicate that CD40Lhigh CD4+ iPS-T
cells have a superior ability to induce DC maturation.
It was previously reported that the CD40L-CD40-medi-
ated ILC3-B cell interactions induce regulatory B cells to
secrete the T cell-suppressing cytokine IL-10 (Komlosi
et al., 2017); thus, we examined whether CD40Lhigh
CD4+ iPS-T cells induce the immune inhibitory cytokine
IL-10 by interacting with DCs or B cells. Both CD40Lhigh-
and CD40Llow-CD4+ iPS-T cells alone did not produce
IL-10 upon CD3 stimulation (Figure S6A). When DCs or
B cells were co-cultured with CD40Lhigh CD4+ iPS-T cells
in the presence of the b3a2 peptide, they did not produce
IL-10, whereas DCs co-cultured with CD40Llow CD4+
iPS-T cells produced IL-10 (Figure S7G). These data indicate
that CD40Lhigh CD4+ iPS-Tcells do not stimulate IL-10 pro-
duction, which is an appropriate property for eliciting anti-
leukemic immune responses.
CD40Lhigh CD4+ iPSC-Derived T Cells Reduced TCR-
Independent Cytotoxicity
CD4+ Th1 clone (SK)-derived iPS-T cells exhibited antigen-
independent cytotoxicity against THP-1, and the cytotox-
icity against THP-1 was partially dependent on perforin
and DNAM-1 (Figure 4A). iPS-T cells exert DNAM-1- and
NKG2D-dependent cytotoxicity against K562 cells express-
ing both DNAM-1 ligand (PVR, nectin-2) and NKG2D li-
gands (MICA/B) (Kitayama et al., 2016). Despite the expres-
sion of both NK receptors, the iPS-T cells used in this study
did not show NKG2D-dependent cytotoxicity (Figure 4A).
This may be because of the reduced expression of NKG2D
ligands (MICA/B) on THP-1 target cells (Figure S7H).
CD40Lhigh CD4+ iPS-T cells conditioned by IL-2/IL-15
Figure 2. CD40Lhigh Population in iPS-T Cells Shows High Responsiveness to TCR Stimulation
(A and B) CD40L expression of indicated iPS-T cells on day 13 after PHA-P stimulation. Mock iPS-T cells or CD4+ iPS-T cells were stimulated
with PHA-P and cultured in the absence (A) or presence (B) of IL-2. The frequency of CD40L-positive cells is shown in the upper right corner
of each panel.
(C and D) Expression of CD40L, CD4, and TCR-Vb22 on the subpopulations are shown. CD40L high and low populations under IL-2
(100 U/mL) and IL-15 (5 ng/mL) were separated from Mock iPS-T cells (C) and CD4+ iPS-T cells (D) by flow cytometry sorting and expanded
by PHA-P stimulation.
(E and F) Surface CD40L expression on different subpopulations (E; CD40L high and F; CD40L low) stimulated with plate-bound control IgG
or anti-CD3 mAb (10 mg/mL). The original CD4+ Th1 clone (SK) served as a control. CD40L (red) and isotype-matched controls (gray) are
shown.
(G) Cytokine production by the indicated population stimulated with plate-bound control IgG or anti-CD3 mAb (10 mg/mL). The original
CD4+ Th1 clone (SK) served as control. (H) Cytokine production by CD40Lhigh CD4+ iPS-T cells (1 3 105) co-cultured with THP1 cells (53
104) expressing HLA-DR9 and BCR-ABL p210 gene. (G and H) The indicated cytokines in the culture supernatant (24 h) were measured by a
bead-based multiplex immunoassay. Data shown are the means ± SD of triplicate cultures and are representative of two independent
triplicate experiments.
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exhibited reduced expression of DNAM-1 and NKG2D
compared with CD40Llow CD4+ iPS-T cells (Figure 4B,
left panel). Consistent with the reduced DNAM-1 and
NKG2D expression, CD40Lhigh CD4+ iPS-T cells reduced
NK cell-like cytotoxicity against THP-1-DR9 while retain-
ing b3a2-specific cytotoxicity (Figure 4B, right panel).
These data indicate that CD40Lhigh CD4+ iPS-T cells
reduced antigen-independent cytotoxicity by downregu-
lating DNAM-1 expression.
CD40Lhigh CD4+ iPSC-Derived T Cells Efficiently
Induce Primary Expansion of Leukemia Ag-Specific
CTLs
CD4+ Th cells help in the priming of CD8+ CTLs via DC
activation (Bennett et al., 1997; Ridge et al., 1998; Schoen-
berger et al., 1998; Ueda et al., 2016). To determinewhether
CD40Lhigh CD4+ iPS-T cells can induce leukemia antigen-
specific CTL responses, vehicle- or b3a2 peptide-loaded
DCs were cultured with CD40Lhigh CD4+ iPS-T cells, and
differentially conditioned DCs were loaded with Wilms
tumor 1 (WT1235-243) peptide, irradiated, and cultured
with CD8+ T cells (Figure S8A). After 7 days of culture, the
proliferation of CD8+ T cells was evaluated. We observed
markedly enhanced proliferation of CD8+ T cells upon
stimulation with WT1235-243 peptide when CD40L
high
CD4+ iPS-T cell/b3a2 peptide-conditioned DCs were used
as antigen-presenting cells (Figure 5A, left panel). In
contrast, neither CD40Llow CD4+ iPS-T cell/b3a2-condi-
tioned DCs nor CD40Llow Mock iPS-T cell/b3a2-condi-
tioned DCs induced the proliferation of CD8+ T cells
(Figure 5A, center and right panel). CTLs stimulated by
CD40Lhigh CD4+ iPS-T cell/b3a2 peptide-conditioned DCs
contained a high frequency of WT1-tetramer-positive
T cells (Figure 5B, left panel). WT1 peptide-specific CTLs
were further expanded by repeated stimulation with WT1
peptide three times (Figure 5B, center panel). The expanded
WT1-specific CTLs exhibited cytotoxic activity against
WT1 peptide-loaded HLA-A24-expressing K562, but not
against vehicle-loaded cells (Figure 5B, right panel). These
data indicate that the activation of CD40Lhigh CD4+ iPS-T
cells by the b3a2 peptide induces DC-mediated cellular
adjuvant properties that can increase leukemic antigen-
specific CTL responses, which is consistent with the T help-
er function of the original CD4+ Th1 clone (SK) (Ueda et al.,
2016).
WT1-Specific CTLs Primed By CD40Lhigh CD4+ iPSC-
Derived T Cell/DC Interaction Exert Anti-leukemic
Effects In Vivo
To examine whether primed WT1 peptide-specific CTLs
exert anti-leukemic effects in vivo, WT1 epitope-expressing
K562 cells were subcutaneously injected into NSG mice
with or without WT1 peptide-specific CTLs. Tumor growth
was monitored each week by bioluminescence imaging and
external calipermeasurements. In the presence ofWT1pep-
tide-specific CTLs, tumor growthwas significantly inhibited
(Figure 6A) and the survival of mice was significantly pro-
longed (Figure 6B). Collectively, leukemic antigen-specific
CTLs primed by the interaction of CD40Lhigh CD4+ iPS-T
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Figure 3. DC Activation Induced by
CD40Lhigh CD4+ iPS-T Cells
(A) Flow cytometry profiles of the surface
molecules on DCs. Vehicle- or b3a2-peptide-
pulsed DCs were cultured for 24 hr with the
CD40Lhigh CD4+ and CD40Llow CD4+ popula-
tion at a DC/CD4+ iPS-T cell ratio of 5:1.
Relative fluorescence intensity (RFI) (%) of
indicated molecule is calculated as follows:
RFI (%) = 100 3 (RFI of b3a2 peptide-
treated cells)/(RFI of vehicle-treated cells).
(B) Cytokine production by DCs co-cultured
with the indicated population. Cytokines
in the culture supernatant were measured
by a bead-based multiplex immunoassay.
The indicated population (1 3 104) was co-
cultured for 24 hr with autologous DCs
(2.5 3 104) that had been prepulsed with
b3a2 peptide (10 mM). The original CD4+ Th1
clone (SK) served as a control.
(A and B) Data shown are the means ± SD of
triplicate cultures and are representative of
two independent experiments.
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DISCUSSION
Although tumor antigen-specific CD4+ Th cells are essen-
tial for inducing downstream activation of diverse tumor
antigen-specific CTLs, it is difficult to obtain clinically suf-
ficient numbers of Th cells for adoptive cell therapy. The
unlimited supply of Th cells from iPSCs may resolve this
issue. To date, studies have not reported the successful gen-
eration of HLA class II-restricted CD4+ Th cells from iPSCs.
We established iPSCs from b3a2-specific CD4+ Th cells (SK)
and induced T-lineage cells (iPS-Tcells) from these cells. Us-
ing the current differentiation protocol, the iPS-T cells
spontaneously failed to express CD4 molecules, and their
gene expression profiles were closer to those of ILC1s/NK
cells than to those of abT cells, which may be partially ex-
plained by insufficient control of the transcription factor
BCL11B for specification to the T cell-lineage (Kitayama
et al., 2016). Bcl11b insufficiency is known to cause biased
lineage-reprogramming fromTcells toNK cells (a lineage of
type 1 ILCs) in conditional knockout mice (Li et al., 2010).
Our iPS-T cells from multiple donors expressed ID2 and
ZBTB16, but not BCL11B (Figure S4F). These features may
partially explain the lineage-shift from T cells to type 1
ILCs during in vitro differentiation.
Modification of CD4 expression in the regenerated cells
and purification of the CD40Lhigh population were per-
formed to acquire ILC1-like cells that can stimulate DCs,
thereby, promoting leukemia antigen-specific CTL re-
sponses. Although the detailed mechanisms of this artifi-
cial TCR signaling in group 1 ILC-like T cells are presently
not known, TCR ligation via antigenic peptide/HLA mole-
cule complexes induced proliferation and cytokine produc-
tion in a manner consistent with that in abT cells.
The interaction between CD40Lhigh CD4+ iPS-T cells and
DCs facilitates the production of chemokines to recruit
CXCR3-expressing effector cells (Figure 3B). IFN-g produc-
tion from these recruited effector cells activates DCs to
amplify the production of chemokines (Groom and Luster,
2011). This positive feedback loop pathway may further
facilitate the recruitment and activation of effector cells
in tumor tissues. In the actual leukemia environment,
CD40Lhigh CD4+ iPS-T cells may condition DCs to take up
leukemia cells and cross-present leukemia-derived anti-
gens, resulting in the activation of diverse CTLs that specif-
ically recognize multiple leukemia antigens, a phenome-
non known as epitope spreading. Chronic myelogenous
leukemia (CML) cells carry a number of well-defined leuke-
mia antigens including BCR-ABL, PR1, and WT1 (Moll-
drem et al., 2000; Rezvani et al., 2003). Moreover, TKI treat-
ment of CML induces various mutations in the BCR-ABL
kinase domain because of resistance. Themutated antigens
may then generate highly immunogenic neoepitopes (Cai
et al., 2012), and these neoepitopes are potential targets

























































































































Figure 4. CD40Lhigh CD4+ iPS-T Cells Reduced
NK Cell-like Cytotoxicity
(A) Left panel: cytotoxic activity of iPS-T cells
to THP-1 cells. Center panel: Mock iPS-T cells
were treated with 10 nM concanamycin A (CMA)
to block perforin. Right panel: Indicated Abs
blocking receptor/ligand interactions were
added. Cytotoxicity of iPS-T cells to THP-1 cells
at an effector/target (E:T) ratio of 2.5:1.
(B) Left panel: representative flow cytometry
profiles of TCR-Vb22, CD4, CD40L, DNAM-1, and
NKG2D on the indicated population. Right
panel: cytotoxic activities of the indicated
population to HLA-DR9-expressing THP-1 cells
loaded with vehicle or b3a2 peptide (5 mM).
(A and B) Cytotoxicity was measured by 51Cr-
release assay for 4 hr at the indicated E:T ratios.
Data are representative of two independent
triplicate experiments.
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However, few suitable animal models are available that
reproduce general reactions of human immune cells,
particularly in HLA class II-restricted helper T cell/DC-
mediated CTL priming and subsequent tumor elimination.
Animal models reconstituted with the human hematopoi-
etic system, immune system, tumor xenograft, and iPS-T
cells derived from the same patient may overcome this
limitation in the future.
Our study is an initial step toward clinically applicable
iPSC-derived T helper-like cell therapy. However, iPSC-
based regenerativemedicine is accompanied by challenges,
such as the fact that these strategies are time-consuming
and expensive. Compared with an autologous setting, the
use of HLA-matched or homozygous HLA-type allogeneic
iPSCs transduced with desired TCR (i.e., obtained TCR se-
quences from this research) may resolve this issue in the
preparation of CD40Lhigh CD4+ iPS-T cells (Neofytou
et al., 2015). In addition, reproducible production of
CD4-expressing iPS-T cells is a prerequisite for their clinical
application. In this study, CD4 gene transduction was per-
formed after re-differentiation of iPSCs to T-lineage cells.
Genome editing of iPSCs enables targeted insertion of the
CD4 transgene into the downstream region of T cell-spe-
cific promoters, such as Lck promoter. Using such a system,
it may be possible to establish an ideal iPSC clone express-
ing transgenes only at an ideal differentiation step when
the promoter is activated. This may provide reproducible
CD4-expressing iPS-T cells with safe profiles for clinical
use. Moreover, establishing a good manufacturing prac-
tice-compliant manufacturing protocol using xenogeneic-
free and feeder cell-free material is essential and currently
under development (Fransen et al., 2011; Neofytou et al.,
2015).
In conclusion, we showed that iPS-T cells from CD4+ Th
clone-derived iPSCs constitute a heterogeneous population
of TCR-expressing group 1 ILC-like lymphoid cells. Gene
modification and cell purification resulted in the acquisi-
tion ofHLA class II-restricted TCR-expressing adjuvant cells
that induce anti-leukemia effects via DCmaturation. These
results support iPS-T cells as a potential platform for novel
adjuvant therapy for leukemia.
EXPERIMENTAL PROCEDURES
Peptide, Cytokines, and Chemicals
HLA-DR9 (DRB1*09:01)-restricted BCR-ABL b3a2-junctional
peptide (ATGFKQSSKALQRPVAS), HLA-A24 (A*24:02)-restricted
modified WT1235–243 epitope peptide (CYTWNQMNL), and
HLA-DR53 (DRB4*01:03)-restricted glutamic acid decarboxylase
65 (GAD65)113-131 peptide (DVMNILLQYVVKSFDRSTK) were
commercially synthesized and supplied at >90% purity (Toray
Research Center, Kamakura, Japan, Scrum, Tokyo, Japan). In the
modified WT1235-243 peptide, Y was substituted for M at amino



















































Figure 5. Induction of Leukemia Anti-
gen-Specific CTLs By CD40Lhigh CD4+ iPS-
T Cells
(A) Proliferative response of CD8+ T cells.
Indicated iPS-T cells (5 3 103) and DCs
(1 3 104) ± b3a2 peptide (5 mM) were
initially co-cultured for 5hr tomature theDCs,
after which DCs and iPS-T cells were irradiated
and cultured with autologous CD8+ T cells
(5 3 104) in the presence of WT1 peptide
(5 mM). The proliferative response (day 7) was
measured as the amount of [3H]thymidine
incorporated. Data shown are the means ± SD
of triplicate cultures and are representative of
two independent experiments.
(B) Left panels: frequency of WT1/HLA-A24
tetramer-positive CD8+ T cells primed by
CD40Lhigh CD4+ iPS-T cell-conditioned DCs.
CD40Lhigh CD4+ iPS-T cells (53 103) and DCs
(1 3 104) prepulsed with b3a2 peptide
(5 mM) were initially co-cultured for 5 hr to
mature the DCs, after which DCs and CD4+
iPS-T cells were irradiated and cultured with autologous CD8+ T cells (53 104) in the presence of WT1 peptide (5 mM). Tetramer staining at
day 10 after stimulation is shown. Center panel: frequency of WT1/HLA-A24 tetramer-positive CD8+ T cells after a third stimulation with
WT1 peptide. Representative flow cytometry profiles of two independent experiments. HIV-env/HLA-A24 tetramer was used as a control.
Right panel: cytotoxic activities of expanded WT1-specific CD8+ T cells against K562-A24 loaded with vehicle or WT1 peptide. Cytotoxicity
was measured by 51Cr-release assay for 4 hr at the indicated E:T ratios. Data are representative of two independent triplicate experiments.
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The following reagents were from commercial sources: recombi-
nant human (rh) IL-2, rhIL-4, and rh granulocyte macrophage col-
ony-stimulating factor (Primmune, Osaka, Japan); rhIL-7, rhIL-15,
and rh fms-related tyrosine kinase 3 ligand (Flt-3L) (PeproTech,
Rocky Hill, NJ, USA); rh basic fibroblast growth factor and PHA-P
(Wako Pure Chemicals Industries, Osaka, Japan); rh vascular endo-
thelial growth factor and rh stem cell factor (R&D Systems, Minne-
apolis, MN, USA); and penicillin-killed Streptococcus pyogenes
(OK432) (Chugai Pharmaceutical, Tokyo, Japan).
Generation of Retrovirus for CD4 Transduction
The human CD4 gene was inserted into pDON-AI2 (Takara Bio,
Shiga, Japan). Transient retroviral particles were produced in
G3T-hi cells (Takara Bio), followed by transduction of PG13 cells
to generate GaLV-pseudotyped retrovirus producer cells (Kaneko
et al., 2001).
Generation of iPSCs Derived from HLA Class II-
Restricted Antigen-Specific CD4+ T Cell Clone
HLA-DR9-restricted b3a2-specific CD4+ Th1 clone (SK) (Ueda
et al., 2016) and HLA-DR53-restricted GAD65113-131 peptide-spe-
cific CD4+ Th clone (SA32.5) (Tabata et al., 1998) were reprog-
rammed to iPSCs by transduction of reprogramming factors by
the Sendai viral system using pSeV[KOSM302L] (kindly provided
by Dr. Nakanishi, AIST, Tsukuba, Japan) as described previously
(Kitayama et al., 2016; Nishimura et al., 2013). The iPSC clones
were negative for residual transgenes, showed pluripotency
characterized by the expression of pluripotency-related mole-
cules and teratoma formation in immunodeficient mice, and
were confirmed to have a normal karyotype (Figure S1). The
use of cells isolated from healthy adults was approved by the
Ethics Committee of Kyoto University, and informed consent
was obtained from all donors in accordance with the Declara-
tion of Helsinki.
T Cell Differentiation from iPSCs and CD4
Transduction
We differentiated iPSCs into T cells using a previously described
method (Nishimura et al., 2013). In brief, clumps of iPSCs were
transferred ontoC3H10T1/2 feeder cells and cultured inEBmedium
containing rh vascular endothelial growth factor. On day 7, rh stem
cell factor and rhFlt-3L were added to the culture. On day 14, he-
matopoietic progenitor cells were collected and transferred onto
OP9-DL1 cells and co-cultured in OP9 medium in the presence of
rhIL-7 and rhFLT-3L. On day 35, regenerated Tcells were stimulated
by PHA-P in the presence of rhIL-7 and rhIL-15 using allogeneic pe-
ripheral blood mononuclear cells (PBMCs) as antigen-presenting
cells at 14-day intervals. Expanded iPSC-Tcells (13 106) were trans-
duced with human CD4 using the RetroNectin-bound virus infec-
tion method, in which retroviral solution was preloaded onto
RetroNectin-coated plates, centrifuged at 2,000 3g for 2 hr at
32C, and rinsedwith 1.5%human serumalbumin PBS, after which
the cells were applied to the virus-preloaded plate for 20 hr. After
10 days of culture, a CD4-positive population (15%–35% of total
cells) was sorted by flow cytometry and restimulated for expansion.
Functional Assay of T Cells
Cell proliferation was evaluated by the [3H]thymidine incorpora-
tion assay, as described previously (Zhang et al., 2015). Cytotoxic
activitywasmeasuredusing the 51Cr-release assay, as described pre-
viously (Zhang et al., 2015). Cytokine levels in the culture superna-
tants were evaluated by ELISA (hIFN-g: eBioscience, SanDiego, CA,
USA) or a bead-based multiplex immunoassay (BD Cytomertic
Beads Array; BD Biosciences, Franklin Lakes, NJ, USA).
CTL Priming and Cytotoxicity Assays
CD8+ T cells and DCs were obtained from the same donor from









































Figure 6. Anti-leukemic Activity of CTLs
Primed By CD40Lhigh CD4+ iPS-T Cell-
Conditioned DCs
(A) In vivo anti-leukemia effect. NSG mice
were subcutaneously injected with mixtures
of K562-A24-Luc-WT1 minigene and either
saline or WT1-specific CTLs. Upper panel:
tumor burden was measured weekly by
bioluminescence imaging. Lower panel: the
average tumor size for each group from day
0 to 42 is shown. Error bars represent ± SD.
*p < 0.05 by unpaired Student’s t test (two-
tailed).
(B) Kaplan-Meier survival curves for treated
and control mice. *p < 0.05 by the log rank
(Mantel-Cox) test. WT1-CTL, n = 10; no
treatment, n = 5.
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were used to induce antigen-specific CTLs to avoid alloreactive re-
sponses. CD8+ T cells were isolated from PBMCs by negative mag-
netic cell sorting using a CD8+ T cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). DCs were cultured for 3 hr in
96-well round plates in the presence or absence of b3a2 peptide,
and then the original CD4+ Th1 clone (SK) or re-differentiated SK
was added to the culture and incubated for 5 hr. After irradiation
at 30 Gy, CD8+ T cells were added together with WT1235–243 pep-
tide. On day 7, we added 1 mCi of [3H]thymidine to the cultures;
after 16-hr incubation, we assessed the proliferative response of
CD8+ T cells in a [3H]thymidine incorporation assay. Another
experiment was performed in the samemanner on day 10. The fre-
quencies of WT1-peptide-specific CTLs were determined by stain-
ing with the HLA-A*2402/WT1235–243 tetramer. We restimulated
the resulting CD8+ T cells withWT1235–243 peptide in the presence
of 35-Gy-irradiated autologous PBMCs. The cells were later used in
cytotoxicity assays and in vivo experiments.
In Vivo Experiments
All in vivo animal studies were approved by the Animal Research
Committee of Kyoto University. Six-week-old female NOD-
SCID IL2Rgcnull (NSG) mice were purchased from Charles River
(Yokohama, Japan) and inoculated subcutaneously in the left
shaved shank with mixtures of K562-Luc-A24-WT1 minigene
(1.0 3 105) cells and either saline or WT1-specific CTLs
(1.0 3 106). The mice were monitored for tumor growth and sur-
vival. Tumor growth was monitored weekly by bioluminescence
imaging for 4 weeks and external caliper measurements until
the mice died or were sacrificed when tumors exceeded
25 mm in diameter.
Retroviral Integration Site Analysis by Linear
Amplification-Mediated PCR
Retroviral integration site analysis was performed using the Retro-
X Integration Site Analysis Kit (Clontech, Mountain View, CA,
USA) according to the manufacturer’s instructions.
Statistical Analysis
STATA version 13.0 (StataCorp LP, College Station, TX, USA) was
used for all statistical analyses. To compare multiple experimental
groups, one-way ANOVA with Bonferroni post hoc test was used to
assess significance; to compare two experimental groups, unpaired
t tests (two-tailed) were used. For statistical analysis of Kaplan-Me-
ier survival curves, a log rank (Mantel-Cox) test was used to calcu-
late p values; p values < 0.05 were considered statistically signifi-
cant and are indicated in the figures by asterisks.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, eight figures, and five tables and can be found with
this article online at https://doi.org/10.1016/j.stemcr.2018.04.
025.
AUTHOR CONTRIBUTIONS
N.U., Y.U., and S. Kaneko designed the study. N.U., R.Z., S. Ki-
tayama, Y.Y., S.I., T.-Y.L., Y.M., C.O., A.W., S.S., Y.N., K.K., H.K.,
Y.U., and S. Kaneko interpreted the data. N.U., Y.U., R.Z., S. Ki-
tayama, Y.Y., M.T., and Y.M. performed the experiments. M.N.
provided critical materials. N.U., R.Z., Y.M., and A.W. analyzed
the data. S.I., Y.K., T.U., T.-Y.L., S.S., K.K., Y.N., H.K., and T.N.
contributed to analyzing and discussing the data. Y.U. and S. Ka-
neko supervised the study. N.U., Y.U., and S. Kaneko wrote the
manuscript.
ACKNOWLEDGMENTS
CSII-EF, pCMV-VSV-G-RSV-Rev, and pCAG-HIVgpwere kindly pro-
vided by Dr. H. Miyoshi (RIKEN BioResource Center, Tsukuba,
Japan). cDNA encoding HLA-DRB1*09:01 (DR9) was kindly pro-
vided byDr. H. Kobayashi (AsahikawaMedical College, Asahikawa,
Japan). We thank Dr. P. Karagiannis (Kyoto University, Kyoto,
Japan) for reading the manuscript. This study was performed as a
research program of the Project for Development of Innovative
Research on Cancer Therapeutics (P-DIRECT) and Core Center
for iPS Cell Research of Research Center Network for Realization
of Regenerative Medicine, Japan Agency for Medical Research
and Development. This study was supported by grants from
Grants-in-Aid ‘‘Carcinogenic Spiral,’’ NagonoMedical Foundation,
the National Cancer Center Research and Development Fund (28-
A-8) and the Takeda Science Foundation. Shin Kaneko is a founder,
shareholder, and scientific advisor at Thya and received research
funding from Kyowa Hakko Kirin, Takeda Pharmaceutical, Sumi-
tomo Chemical, and Thyas. Hitoshi Kiyoi received research fund-
ing from Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa
Hakko Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Nippon
Boehringer Ingelheim, Astellas Pharma, and Celgene Corporation,
consulting fees from Astellas Pharma and Daiichi Sankyo, and
honoraria from Bristol-Myers Squibb. The remaining authors
declare no competing financial interests.
Received: October 10, 2017
Revised: April 27, 2018
Accepted: April 30, 2018
Published: May 24, 2018
REFERENCES
Bennett, S.R., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.,
and Heath, W.R. (1998). Help for cytotoxic-T-cell responses is
mediated by CD40 signalling. Nature 393, 478–480.
Bennett, S.R., Carbone, F.R., Karamalis, F., Miller, J.F., and Heath,
W.R. (1997). Induction of a CD8+ cytotoxic T lymphocyte
response by cross-priming requires cognate CD4+ T cell help.
J. Exp. Med. 186, 65–70.
Boise, L.H., Minn, A.J., Noel, P.J., June, C.H., Accavitti, M.A.,
Lindsten, T., and Thompson, C.B. (1995). CD28 costimulation
can promote Tcell survival by enhancing the expression of Bcl-XL.
Immunity 3, 87–98.
Cai, A., Keskin, D.B., DeLuca, D.S., Alonso, A., Zhang, W., Zhang,
G.L., Hammond, N.N., Nardi, V., Stone, R.M., Neuberg, D., et al.
(2012). Mutated BCR-ABL generates immunogenic T-cell epitopes
in CML patients. Clin. Cancer Res. 18, 5761–5772.
10 Stem Cell Reports j Vol. 10 j 1–12 j June 5, 2018
Please cite this article in press as: Ueda et al., Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-
Mediated Anti-leukemic Cell Response, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.04.025
Carbone, E., Ruggiero, G., Terrazzano, G., Palomba, C., Manzo, C.,
Fontana, S., Spits, H., Karre, K., and Zappacosta, S. (1997). A new
mechanism of NK cell cytotoxicity activation: the CD40-CD40
ligand interaction. J. Exp. Med. 185, 2053–2060.
Cording, S., Medvedovic, J., Aychek, T., and Eberl, G. (2016).
Innate lymphoid cells in defense, immunopathology and immu-
notherapy. Nat. Immunol 17, 755–757.
Fransen, M.F., Sluijter, M., Morreau, H., Arens, R., and Melief, C.J.
(2011). Local activation of CD8 Tcells and systemic tumor eradica-
tionwithout toxicity via slow release and local delivery of agonistic
CD40 antibody. Clin. Cancer Res. 17, 2270–2280.
Groom, J.R., and Luster, A.D. (2011). CXCR3 in T cell function.
Exp. Cell Res. 317, 620–631.
Janeway, C.A., Jr. (1992). The T cell receptor as a multicomponent
signallingmachine: CD4/CD8 coreceptors and CD45 in T cell acti-
vation. Annu. Rev. Immunol. 10, 645–674.
Kaneko, S., Onodera, M., Fujiki, Y., Nagasawa, T., and Nakauchi, H.
(2001). Simplified retroviral vector gcsap with murine stem cell
virus long terminal repeat allows high and continued expression
of enhanced green fluorescent protein by human hematopoietic
progenitors engrafted in nonobese diabetic/severe combined
immunodeficient mice. Hum. Gene Ther. 12, 35–44.
Kim, H.J., and Cantor, H. (2014). CD4 T-cell subsets and tumor im-
munity: the helpful and the not-so-helpful. Cancer Immunol. Res.
2, 91–98.
Kitayama, S., Zhang, R., Liu, T.Y., Ueda,N., Iriguchi, S., Yasui, Y., Ka-
wai, Y., Tatsumi, M., Hirai, N., Mizoro, Y., et al. (2016). Cellular
adjuvant properties, direct cytotoxicity of re-differentiated Val-
pha24 invariant NKT-like cells from human induced pluripotent
stem cells. Stem Cell Rep 6, 213–227.
Komlosi, Z.I., Kovacs, N., van de Veen, W., Kirsch, A.I., Fahrner,
H.B., Wawrzyniak, M., Rebane, A., Stanic, B., Palomares, O., Ruck-
ert, B., et al. (2017). Human CD40 ligand-expressing type 3 innate
lymphoid cells induce IL-10-producing immature transitional reg-
ulatory B cells. J. AllergyClin. Immunol. https://doi.org/10.1016/j.
jaci.2017.07.046.
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M.,
Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., et al.
(2015). Mutant MHC class II epitopes drive therapeutic immune
responses to cancer. Nature 520, 692–696.
Li, L., Leid, M., and Rothenberg, E.V. (2010). An early T cell lineage
commitment checkpoint dependent on the transcription factor
Bcl11b. Science 329, 89–93.
Magri, G., Miyajima, M., Bascones, S., Mortha, A., Puga, I., Cassis,
L., Barra, C.M., Comerma, L., Chudnovskiy, A., Gentile, M., et al.
(2014). Innate lymphoid cells integrate stromal and immunolog-
ical signals to enhance antibody production by splenic marginal
zone B cells. Nat. Immunol 15, 354–364.
McKenzie, A.N., Spits, H., and Eberl, G. (2014). Innate lymphoid
cells in inflammation and immunity. Immunity 41, 366–374.
Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M.,
Champlin, R.E., and Davis, M.M. (2000). Evidence that specific T
lymphocytes may participate in the elimination of chronic mye-
logenous leukemia. Nat. Med. 6, 1018–1023.
Naito, T., Tanaka, H., Naoe, Y., and Taniuchi, I. (2011). Transcrip-
tional control of T-cell development. Int. Immunol. 23, 661–668.
Neofytou, E., O’Brien, C.G., Couture, L.A., and Wu, J.C. (2015).
Hurdles to clinical translation of human induced pluripotent
stem cells. J. Clin. Invest 125, 2551–2557.
Nishimura, T., Kaneko, S., Kawana-Tachikawa, A., Tajima, Y., Goto,
H., Zhu, D., Nakayama-Hosoya, K., Iriguchi, S., Uemura, Y., Shi-
mizu, T., et al. (2013). Generation of rejuvenated antigen-specific
T cells by reprogramming to pluripotency and redifferentiation.
Cell Stem Cell 12, 114–126.
Rezvani, K., Grube, M., Brenchley, J.M., Sconocchia, G., Fujiwara,
H., Price, D.A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R.,
et al. (2003). Functional leukemia-associated antigen-specific
memory CD8+ T cells exist in healthy individuals and in patients
with chronic myelogenous leukemia before and after stem cell
transplantation. Blood 102, 2892–2900.
Ridge, J.P., Di Rosa, F., andMatzinger, P. (1998). A conditioned den-
dritic cell can be a temporal bridge between a CD4+ T-helper and a
T-killer cell. Nature 393, 474–478.
Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., and
Melief, C.J. (1998). T-cell help for cytotoxic T lymphocytes is medi-
ated by CD40-CD40L interactions. Nature 393, 480–483.
Sonnenberg, G.F., and Artis, D. (2015). Innate lymphoid cells in
the initiation, regulation and resolution of inflammation. Nat.
Med. 21, 698–708.
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P.,
Eberl, G., Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius,
R.E., et al. (2013). Innate lymphoid cells – a proposal for uniform
nomenclature. Nat. Rev. Immunol. 13, 145–149.
Summers deLuca, L., and Gommerman, J.L. (2012). Fine-tuning of
dendritic cell biology by the TNF superfamily. Nat. Rev. Immunol.
12, 339–351.
Tabata, H., Kanai, T., Yoshizumi, H., Nishiyama, S., Fujimoto, S.,
Matsuda, I., Yasukawa, M., Matsushita, S., and Nishimura, Y.
(1998). Characterization of self-glutamic acid decarboxylase 65-
reactive CD4+ T-cell clones established from Japanese patients
with insulin-dependent diabetes mellitus. Hum. Immunol. 59,
549–560.
Ueda, N., Zhang, R., Tatsumi, M., Liu, T.Y., Kitayama, S., Yasui, Y.,
Sugai, S., Iwama, T., Senju, S., Okada, S., et al. (2016). BCR-ABL-
specific CD4+ T-helper cells promote the priming of antigen-spe-
cific cytotoxic T cells via dendritic cells. Cell. Mol. Immunol 15,
15–26.
Vizcardo, R., Masuda, K., Yamada, D., Ikawa, T., Shimizu, K., Fujii,
S., Koseki, H., and Kawamoto, H. (2013). Regeneration of human
tumor antigen-specific T cells from iPSCs derived from mature
CD8(+) T cells. Cell Stem Cell 12, 31–36.
Wakao, H., Yoshikiyo, K., Koshimizu, U., Furukawa, T., Enomoto,
K., Matsunaga, T., Tanaka, T., Yasutomi, Y., Yamada, T., Minakami,
H., et al. (2013). Expansion of functional human mucosal-associ-
ated invariant Tcells via reprogramming to pluripotency and redif-
ferentiation. Cell Stem Cell 12, 546–558.
Wiesel, M., and Oxenius, A. (2012). From crucial to negligible:
functional CD8(+) T-cell responses and their dependence on
CD4(+) T-cell help. Eur. J. Immunol. 42, 1080–1088.
Stem Cell Reports j Vol. 10 j 1–12 j June 5, 2018 11
Please cite this article in press as: Ueda et al., Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-
Mediated Anti-leukemic Cell Response, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.04.025
Yamada, D., Iyoda, T., Vizcardo, R., Shimizu, K., Sato, Y., Endo, T.A.,
Kitahara, G., Okoshi, M., Kobayashi, M., Sakurai, M., et al. (2016).
Efficient regeneration of humanValpha24+ invariant natural killer
T cells and their anti-tumor activity in vivo. Stem Cells 34, 2852–
2860.
Zhang, R., Liu, T., Senju, S., Haruta, M., Hirosawa, N., Suzuki, M.,
Tatsumi, M., Ueda, N., Maki, H., Nakatsuka, R., et al. (2015). Gen-
eration of mouse pluripotent stem cell-derived proliferating
myeloid cells as an unlimited source of functional antigen-present-
ing cells. Cancer Immunol. Res. 3, 668–677.
12 Stem Cell Reports j Vol. 10 j 1–12 j June 5, 2018
Please cite this article in press as: Ueda et al., Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-
Mediated Anti-leukemic Cell Response, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.04.025
